Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 15

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 15
---
EX F – DELAWARE CERTIFICATE OF CONVERSION                  |     |      | F-1  |
| ANNEX G – DELAWARE CERTIFICATE OF INCORPORATION               |     |      | G-1  |
| ANNEX H – DELAWARE BYLAWS                                     |     |      | H-1  |
| PART II                                                       |     |      | II-1 |
| SIGNATURES                                                    |     |      | II-8 |

ii

FREQUENTLY USED TERMS Unless otherwise indicated or the context requires otherwise, when used in this joint proxy statement/prospectus:

| • |     | “2023 Company Warrants” refers to any warrants to purchase shares of Kineta Common Stock issued by the Company during 2023, pursuant to warrant agreements entered into between the Company and the respective warrant holder; |

| • |     | “acceptable confidentiality agreement” has the meaning ascribed to it in “The Merger Agreement—No Solicitation by Kineta – Fiduciary Exception”; |

| • |     | “Acquisition Proposal” refers to any inquiry, proposal or offer from any Person or group of Persons other than TuHURA or one of its subsidiaries for (i) a merger, reorganization, consolidation, tender offer, exchange offer, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving an acquisition of the Company or any subsidiary or subsidiaries of the Company whose business constitutes 20% or more of the net revenues, net income or assets of the Company and its subsidiaries, taken as a whole (for the twelve (12) month period ending on the last day of the Company’s most recently completed fiscal quarter) or (ii) the acquisition in any manner, directly or indirectly, of over 20% of the equity securities or consolidated total assets of the Company and its subsidiaries, in each case other than the Mergers and the other transactions contemplated by the Merger Agreement, other than any inquiry, proposal or offer relating to a Permitted Asset Disposition; |

| • |     | “Adverse Recommendation Change” has the meaning ascribed to it the section “The Merger Agreement—No Solicitation by Kineta – Fiduciary Exception”; |

| • |     | “Annual Meeting Proposals” means the Director Election Proposal, Executive Compensation Proposal and the Auditor Ratification Proposal to be voted on at the TuHURA special meeting in lieu of an annual meeting; |

| • |     | “